GlassScriptPhysician profile
James L Roth
NPI 1528055589
$1,733.89
in general payments reported to CMS, 2019-2025
23 companies · $70.60 in 2025
The $70.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.69 · 2021: $111 · 2022: $617 · 2023: $527 · 2024: $394 · 2025: $70.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $225.94 | 2024 | Inspire |
| Lilly USA, LLC | $208.65 | 2022-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $165.59 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.43 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $110.47 | 2019-2023 | Shingrix |
| Novo Nordisk INC | $100.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $95.26 | 2022-2023 | |
| Abbott Laboratories | $83.17 | 2022-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $75.10 | 2021-2023 | Austedo, Ajovy |
| Astrazeneca Pharmaceuticals LP | $67.15 | 2022-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $64.51 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.81 | 2022-2023 | |
| Exact Sciences Corporation | $49.54 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.98 | 2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $41.06 | 2022-2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $36.25 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $26.98 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $23.47 | 2021 | |
| Lundbeck LLC | $21.48 | 2023 | Rexulti |
| Abbvie INC. | $21.33 | 2021 | |
| Medtronic, INC. | $19.22 | 2024 | Interstim |
| Heartflow, INC. | $15.73 | 2022 | |
| Amgen INC. | $15.02 | 2023 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.